Skip to main content
SpringerLink
Log in

Cyproteronacetat und Meningeomrisiko

Cyproterone acetate and risk of meningioma

  • Arzneimitteltherapie
  • Published:
Gynäkologische Endokrinologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ostrom QT, Gittleman H, Xu J et al (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro-Oncology 18(5):v1–v75

    Article  Google Scholar 

  2. Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99:307–314

    Article  Google Scholar 

  3. Lin DD, Lin JL, Deng XY, Li W, Li DD, Yin B, Lin J, Zhang N, Sheng HS (2019) Trends in intracranial meningioma incidence in the United States, 2004–2015. Cancer Med 8(14):6458–6467

    Article  Google Scholar 

  4. Ter Wengel PV, Martin E, Gooren L, Den Heijer M, Peerdeman SM (2016) Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature. Andrologia 48(10):1130–1137

    Article  CAS  Google Scholar 

  5. Hatiboglu MA, Cosar M, Iplikcioglu AC, Ozcan D (2008) Sex steroid and epidermal growth factor profile of giant meningiomas associated with pregnancy. Surg Neurol 69(4):356–363

    Article  Google Scholar 

  6. Smith JS, Quiñones-Hinojosa A, Harmon-Smith M, Bollen AW, McDermott MW (2005) Sex steroid and growth factor profile of a meningioma associated with pregnancy. Can J Neurol Sci 32(1):122–127

    Article  Google Scholar 

  7. Schoenberg BS, Christine BW, Whisnant JP (1975) Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 25(8):705–712

    Article  CAS  Google Scholar 

  8. Rao G, Giordano SH, Liu J, McCutcheon IE (2009) The association of breast cancer and meningioma in men and women. Neurosurgery 65(3):483–489

    Article  Google Scholar 

  9. Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH (2000) Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 65(10–11):795–800

    Article  CAS  Google Scholar 

  10. Gabos S, Berkel J (1992) Meta-analysis of progestin and estrogen receptors in human meningiomas. Neuroepidemiology 11(4–6):255–260

    Article  CAS  Google Scholar 

  11. Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, Wang Z (2013) Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. PLoS One 8(12):e83261

    Article  Google Scholar 

  12. Benson VS, Pirie K, Green J, Bull D, Casabonne D, Reeves GK, Beral V (2019) Hormone replacement therapy and incidence of central nervous system tumours in the million women study. Neuro-Oncology 21(4):498–507

    Article  Google Scholar 

  13. Muskens IS, Wu AH, Porcel J, Cheng I, Le Marchand L, Wiemels JL, Setiawan VW (2019) Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the multiethnic cohort. Neuro-Oncology 21(4):498–507

    Article  Google Scholar 

  14. Andersen L, Friis S, Hallas J, Ravn P, Schrøder HD, Gaist D (2013) Hormone replacement therapy increases the risk of cranial meningioma. Eur J Cancer 49(15):3303–3310

    Article  CAS  Google Scholar 

  15. Froelich S, Dali-Youcef N, Boyer P, Kehrli P, Maitrot D, Auwerx J, Schlienger JL (2008) Does cyproterone acetate promote multiple meningiomas? EJEA 16:P158

    Google Scholar 

  16. Gil M, Oliva B, Timoner J, Maciá MA, Bryant V, de Abajo FJ (2011) Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol 72(6):965–968

    Article  CAS  Google Scholar 

  17. Cea-Soriano L, Blenk T, Wallander MA, Rodríguez LA (2012) Hormonal therapies and meningioma: is there a link? Cancer Epidemiol 36(2):198–205

    Article  CAS  Google Scholar 

  18. Schildkraut JM, Calvocoressi L, Wang F et al (2014) Endogenous and exogenous hormone exposure and the risk of meningioma in men. J Neurosurg 120(4):820–826

    Article  Google Scholar 

  19. Giraldi L, Hansen JV, Wohlfahrt J et al (2019) Male hormone-interfering drugs and meningioma development. Neurooncol Adv 1(1):vdz46

    PubMed  PubMed Central  Google Scholar 

  20. Sys C, Kestelyn P (2015) Unilateral proptosis and blindness caused by meningioma in a patient treated with cyproterone acetate. GMS Ophthalmol Cases 5:Doc5

    PubMed  PubMed Central  Google Scholar 

  21. Bernat AL, Bonnin S, Labidi M, Aldahak N, Bresson D, Bouazza S, Froelich S (2018) Regression of giant olfactory groove meningioma and complete visual acuity recovery after discontinuation of cyproterone acetate. J Ophthalmic Vis Res 13(3):355–358

    Article  Google Scholar 

  22. Raj R, Korja M, Koroknay-Pál P, Niemelä M (2018) Multiple meningiomas in two male-to-female transsexual patients with hormone replacement therapy: a report of two cases and a brief literature review. Surg Neurol Int 9:109

    Article  Google Scholar 

  23. Portet S, Naoufal R, Tachon G, Simonneau A, Chalant A, Naar A, Milin S, Bataille B, Karayan-Tapon L (2019) Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment. Neurooncol Adv 1(1):vdz3

    PubMed  PubMed Central  Google Scholar 

  24. Weill A et al (2019) Exposition prolongée à de fortes doses d’acétate de cyprotérone et risque de méningiome chez la femme. https://www.ansm.sante.fr/var/ansm_site/storage/original/application/b632fbd0387cd9e80a8312469ed52d2a.pdf. Zugegriffen: 04.07.2020

  25. BfArM (2020) Rote-Hand-Brief zu Cyproteronacetat: Anwendungsbeschränkungen aufgrund des Risikos für Meningeome. www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2020/rhb-cyproteron.pd. Zugeriffen: 11.07.2020

  26. EMA (2020) Assessment report. Referral under article 31 of directive 2001/83/EC resulting from pharmacovigilance data. INN/active substance: cyproterone. www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-prac-assessment-report_en.pdf. Zugegriffen: 11.07.2020

Download references

Author information

Authors and Affiliations

  1. Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Münster, 48149, Münster, Deutschland

    Tanja Sperlbaum & Ludwig Kiesel

  2. UKM Kinderwunschzentrum, Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Münster, 48149, Münster, Deutschland

    Tanja Sperlbaum

Authors
  1. Tanja Sperlbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ludwig Kiesel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tanja Sperlbaum.

Ethics declarations

Interessenkonflikt

T. Sperlbaum und L. Kiesel geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

B. Leeners, Zürich

O. Ortmann, Regensburg

C. Tempfer, Herne

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sperlbaum, T., Kiesel, L. Cyproteronacetat und Meningeomrisiko. Gynäkologische Endokrinologie 19, 63–67 (2021). https://doi.org/10.1007/s10304-020-00365-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-020-00365-4

Search

Navigation